Answers are grounded in this paper and cite their sources.
Coronavirus disease-2019, which was declared by the WHO as a global pandemic in March 2020, was seen to be associated with high incidence of thromboembolic complication. The use of prophylactic anticoagulation was seen to have a survival benefit, especially in high-risk patients. The use of higher than standard-dose prophylaxis anticoagulation in critically ill patients may be warranted. There is no recommendation regarding the use of therapeutic dose anticoagulation, except for very high-risk patients only transiently until proving or disproving the presence of thromboembolic complications.
No takes yet. Share an insight, caveat, or question.
Khaled M. Taema (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: